US 12,465,635 B2
Methods of treating inflammatory arthritis using secukinumab
Shephard Mpofu, Oberwil (CH); Hanno Richards, Therwil (CH); Karthinathan Thangavelu, Geneva (CH); and Matthias Machacek, Allschwil (CH)
Assigned to NOVARTIS AG, Basel (CH)
Filed by NOVARTIS AG, Basel (CH)
Filed on Dec. 8, 2021, as Appl. No. 17/545,894.
Application 17/545,894 is a division of application No. 16/439,423, filed on Jun. 12, 2019, abandoned.
Application 16/439,423 is a division of application No. 15/654,854, filed on Jul. 20, 2017, granted, now 10,363,307.
Application 15/654,854 is a division of application No. 13/877,585, granted, now 9,744,234, issued on Aug. 29, 2017, previously published as PCT/EP2011/069476, filed on Nov. 4, 2011.
Claims priority of provisional application 61/410,533, filed on Nov. 5, 2010.
Prior Publication US 2022/0193234 A1, Jun. 23, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61K 31/519 (2006.01); A61K 45/06 (2006.01); C07K 16/24 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/3955 (2013.01) [A61K 31/519 (2013.01); A61K 45/06 (2013.01); C07K 16/244 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55 (2013.01); C07K 2317/21 (2013.01); C07K 2317/34 (2013.01); C07K 2317/76 (2013.01); C07K 2317/90 (2013.01)] 18 Claims
 
1. A method of treating inflammatory arthritis in a patient in need thereof using secukinumab, wherein the method comprises subcutaneously administering every 2 weeks or every 4 weeks about 75 mg to about 300 mg of secukinumab to the patient, wherein the inflammatory arthritis is spondyloarthropathy or polymyalgia rheumatica.